Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis


Creative Commons License

Kalincik T., Horakova D., Spelman T., Jokubaitis V., Trojano M., Lugaresi A., ...Daha Fazla

ANNALS OF NEUROLOGY, cilt.77, ss.425-435, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 77 Konu: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1002/ana.24339
  • Dergi Adı: ANNALS OF NEUROLOGY
  • Sayfa Sayıları: ss.425-435

Özet

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.